Congresses

Title Yearsort ascending
Novel in vitro synergistic combinations in the treatment of non-tuberculous mycobacteria 2021
Enzymatic inhibition of Mycobacterium tuberculosis DprE1 protein by the anti-parasitic selamectin lacks translation into phenotypic activity 2021
Approaches to elucidate the mode of action of a novel chemical series active against mycobacteria 2021
Repurposing beta-lactams for Buruli ulcer therapy, from the bench to the clinic. 2021
Strategies to elucidate the mode of action of the avermectins against mycobacteria 2021
Beta-lactams against Mycobacterium kansasii 2021
Expert Campus | Focus on tuberculosis 2020
Fighting Mycobacterium abscessus infection in Cystic Fibrosis patients 2020
Expert campus | Focus on tuberculosis 2020
Repurposing beta-lactams for Buruli ulcer therapy 2020
Discovering the mode of action of a novel chemical series active against mycobacteria and other microbial pathogens 2020
Repurposing beta-lactams for Buruli ulcer therapy 2020
Repurposing avermectins for the treatment of infections by non-tuberculous mycobacteria 2020
Development Of An Efficient In Vitro High-Throughput Method To Discover New Combinatorial Therapies Against Non-Tuberculous Mycobacteria 2020
IMPLEMENTATION OF THE HOLLOW FIBER SYSTEM FOR ANTIMICROBIAL RESEARCH 2020
Resistance to selamectin in Mycobacterium smegmatis is associated with changes in the mycobacterial envelope 2020
Mode of action elucidation studies of the avermectins against Mycobacteria 2019
DEVELOPMENT OF A HIGH-THROUGHPUT METHOD FOR SYNERGISTIC DRUG COMBINATIONS SCREENING 2019
Beta-lactams for Tuberculosis Treatment 2019
Mode of action elucidation studies of a new chemical series active against Mycobacteria and other microbial pathogens 2019

Pages